# Brazil SUS pharmaceutical expansion > Live situation record from CLSTR: https://clstr.news/situations/brazil-sus-pharmaceutical-expansion > Updated: 2026-09-08T01:45:53.000Z. Sources: 51. Developments: 4. Brazil’s Unified Health System (SUS) is expanding its pharmaceutical offerings through new investments and specialized programs. In late August, the Tripartite Inter-Agency Commission (CIT) approved an expansion to include subcutaneous infliximab for patients with moderate to severe Crohn’s disease. This R$ 59.1 million investment aims to benefit over 13,500 people by allowing for home administration, reducing the need for hospital visits. The decision also established new responsibilities for treating non-infectious uveitis, ANCA-associated vasculitis, advanced chronic kidney disease, and mercury poisoning. Starting in October 2026, the Ministry of Health will incorporate three high-technology medications for lung cancer treatment into SUS: brigatinib, gefitinib, and durvalumab. Brigatinib and gefitinib are oral targeted therapies that act on specific cancer cell alterations and can be administered at home with fewer side effects than traditional chemotherapy. Durvalumab is an immunotherapy indicated for stage III lung cancer patients who are ineligible for surgery. The Ministry noted that these treatments have demonstrated improvements in overall patient survival. To support this expansion, the Ministry of Health has finalized the regulations for the Oncology Pharmaceutical Assistance (AF-Onco) component. This regulatory framework establishes new standards for the management, acquisition, and distribution of oncology drugs, coordinating efforts between federal, state, and municipal governments to align with the National Cancer Prevention and Control Policy. These treatments will be fully funded via the AF-Onco program. While these specific medications are expected to benefit approximately 1,900 patients, the broader AF-Onco initiative aims to increase the availability of high-cost oncology treatments in the public network by 35%, with an estimated annual budget of R$ 2.1 billion reaching over 100,000 people through the provision of 23 high-cost oncological drugs. ## Claims - Three new lung cancer medications will be available through the SUS starting in October. (corroborated by 22 sources) - The new lung cancer drugs include brigatinib, gefitinib, and durvalumab. (corroborated by 22 sources) - Approximately 1,900 patients are expected to be treated with these lung cancer medications. (corroborated by 22 sources) - The federal government will fully fund these medications through the Oncology Pharmaceutical Assistance (AF-Onco) program. (corroborated by 22 sources) - The AF-Onco program will offer 23 high-cost oncology drugs, increasing public treatment availability by 35%. (corroborated by 22 sources) ## Timeline ### 2026-09-08: Brazil incorporates three high-tech lung cancer drugs into SUS Brazil's Ministry of Health is incorporating three advanced lung cancer drugs into the SUS and has finalized regulations for the AF-Onco program to improve oncology medication management. 2 sources. https://clstr.news/cluster/brazil-incorporates-three-high-tech-lung-cancer-drugs-into-sus ### 2026-08-31: Brazil to add three lung cancer drugs to SUS in October Brazil's Ministry of Health will add three high-tech lung cancer drugs—brigatinib, gefitinib, and durvalumab—to the SUS in October, funded by the new AF-Onco program to benefit thousands of patients. 35 sources. https://clstr.news/cluster/brazil-to-provide-three-new-lung-cancer-drugs-through-sus ### 2026-08-30: Brazil joins global Hepatitis B research and expands cancer drug access Brazil joins a global Johns Hopkins-led study to find a Hepatitis B cure, while SUS expands lung cancer treatment with three new high-cost medications. 11 sources. https://clstr.news/cluster/global-research-consortium-targets-hepatitis-b-cure ### 2026-08-27: Brazil's SUS expands medication access for Crohn's disease Brazil's SUS will invest up to R$ 59.1 million to provide subcutaneous infliximab for Crohn's disease, allowing home treatment for over 13,500 patients, alongside new medications for uveitis and vasculitis. 4 sources. https://clstr.news/cluster/brazils-sus-expands-medication-access-for-crohns-disease --- Cite as: Brazil SUS pharmaceutical expansion. CLSTR, https://clstr.news/situations/brazil-sus-pharmaceutical-expansion